What's Happening?
Mosaic Therapeutics, an oncology therapeutics company, has announced the appointment of Dr. Stephen Shuttleworth as its new Chief Scientific Officer (CSO). Dr. Shuttleworth brings over 30 years of experience
in pharmaceutical science, having previously held senior roles at Karus Therapeutics and as a Venture Partner at Samsara BioCapital. His expertise lies in small molecule cancer therapeutics, with a focus on research and development in oncology, immunology, and metabolic disorders. At Mosaic, Dr. Shuttleworth will lead the company's scientific strategy and preclinical pipeline development, focusing on precision combination therapies for cancer treatment. He succeeds Dr. Barry Davies, who is retiring at the end of November.
Why It's Important?
The appointment of Dr. Shuttleworth is significant for Mosaic Therapeutics as it aims to strengthen its leadership in precision oncology. His extensive background in small molecule therapeutics and experience in leading R&D programs will be crucial as the company seeks to advance its pipeline of biomarker-defined, targeted therapies. This move is expected to enhance Mosaic's capabilities in developing innovative cancer treatments, potentially benefiting patients with specific genetic profiles. The leadership change also underscores the company's commitment to expanding its clinical programs and leveraging its experimental and computational platforms to identify effective oncology combinations.
What's Next?
Mosaic Therapeutics plans to commence its first clinical combination study in 2026, focusing on its lead products, ASTX029 and ASTX295, which are in-licensed from Astex Pharmaceuticals. Under Dr. Shuttleworth's leadership, the company will continue to build its pipeline of precision oncology programs, aiming to bring these therapies into clinical settings. The industry will be watching closely to see how Mosaic's approach to synergistic precision oncology evolves and impacts the broader field of cancer treatment.
